Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

BACKGROUND: Nab-paclitaxel plus gemcitabine (nabP+gemcitabine) offers modest survival gains for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Sequential scheduling of nabP+gemcitabine in a PDAC mouse model improved efficacy; this hypothesis was tested in a clinical trial. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrie, P. G., Qian, W., Basu, B., Valle, J. W., Falk, S., lwuji, C., Wasan, H., Palmer, D., Scott-Brown, M., Wadsley, J., Arif, S., Bridgewater, J., Propper, D., Gillmore, R., Gopinathan, A., Skells, R., Bundi, P., Brais, R., Dalchau, K., Bax, L., Chhabra, A., Machin, A., Dayim, A., McAdam, K., Cummins, S., Wall, L., Ellis, R., Anthoney, A., Evans, J., Ma, Y. T., Isherwood, C., Neesse, A., Tuveson, D., Jodrell, D. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283477/
https://www.ncbi.nlm.nih.gov/pubmed/32350413
http://dx.doi.org/10.1038/s41416-020-0846-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283477/
https://www.ncbi.nlm.nih.gov/pubmed/32350413
http://dx.doi.org/10.1038/s41416-020-0846-2

Ejemplares similares